News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

IHC Testing Could Serve as Surrogate to NGS for Early Detection of TP53-Mutant MDS/AML

Original Publication Date
Article Source
External Web Content
Immunohistochemistry (IHC) could represent a biomarker for the early detection of TP53 mutations and for the prediction of a TP53 allelic state in patients with myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML), according to data from an observational trial…

Curing the Incurable: TP53 Mutated Myeloid Neoplasms

Original Publication Date
Article Source
External Web Content
Abstract The TP53 gene ensures genetic fidelity by regulating cell cycle kinetics and apoptosis. In myeloid neoplasms, TP53 mutation is witnessed in 13% of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Alterations in TP53 or its respective protein is…

Clinical Study on Targeted Drug Expands Treatment Options for Myelodysplastic Syndrome

Original Publication Date
Article Source
External Web Content
Their research led to the 2022 approval of olutasidenib for certain patients with IDH1-mutant AML, which occurs in about 10% of AML. After that success, Dr. Watts and his team began to focus closely on testing the drug in MDS, a related condition that often progresses to AML. IDH…

Combo eprenetapopt plus azacitidine is well-tolerated in TP53-mutated MDS and AML

Original Publication Date
Article Source
External Web Content
A phase 2 study found that eprenetapopt plus azacitidine induced responses in patients with TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This combination may be an opportune bridge to transplantation, according to David A. Sallman, MD, of the…

Combo eprenetapopt plus azacitidine is well-tolerated in TP53-mutated MDS and AML

Original Publication Date
Article Source
External Web Content
A phase 2 study found that eprenetapopt plus azacitidine induced responses in patients with TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This combination may be an opportune bridge to transplantation, according to David A. Sallman, MD, of the…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families